Loading
Tracking a tumour's own mutations in blood after surgery for early breast cancer predicted relapse with a 25-fold hazard and a median lead of nearly eight months, and the DNA in the blood foretold the genetics of the eventual metastases better than the primary did.
In a prospective cohort of 55 early breast cancer patients receiving neoadjuvant chemotherapy, detection of ctDNA after apparently curative treatment, at a single post-surgical time point or with serial samples, predicted metastatic relapse (HR 25.1 and 12.0). Serial mutation tracking increased sensitivity with a median lead time of 7.9 months over clinical relapse. Targeted capture sequencing of ctDNA defined the genetic events of minimal residual disease and predicted the metastatic genotype more accurately than sequencing of the primary.
The proof-of-principle paper for molecular residual disease in breast cancer, and the origin of the personalised digital PCR approach that c-TRAK TN later tested prospectively in TNBC.
Shares Nicholas Turner, ctDNA MRD positivity (molecular residual disease after curative treatment), The Institute of Cancer Research, The Royal Marsden.
Shares Nicholas Turner, ctDNA MRD positivity (molecular residual disease after curative treatment), The Institute of Cancer Research, The Royal Marsden.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Triple-negative breast cancer (TNBC).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).